Abstract
We conducted this study to investigate the long-term outcomes of sulfonylurea (SU) use in patients with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D). We used propensity-score matching to identify 6008 pairs of SU users and nonusers from Taiwan’s National Health Insurance Research Database from 1 January 2000 to 31 December 2017. Cox proportional hazard models were used to compare the risks of mortality, cardiovascular events, non-invasive positive pressure ventilation, invasive mechanical ventilation, bacterial pneumonia, lung cancer, and hypoglycemia between SU users and nonusers. In the matched cohorts, the mean follow-up time for SU users and nonusers was 6.57 and 5.48 years, respectively. Compared with nonusers, SU users showed significantly lower risks of mortality [aHR 0.53(0.48–0.58)], cardiovascular events [aHR 0.88(0.81–0.96)], non-invasive positive pressure ventilation [aHR 0.74(0.6–0.92)], invasive mechanical ventilation [aHR 0.57(0.5–0.66)], and bacterial pneumonia [aHR 0.78(0.7–0.87)]. A longer cumulative duration of SU use was associated with a lower risk of these outcomes. This nationwide cohort study demonstrated that SU use was associated with significantly lower risks of cardiovascular events, ventilation use, bacterial pneumonia, and mortality in patients with COPD and T2D. SU may be a suitable option for diabetes management in these patients.
Funder
The Ministry of Health and Welfare Clinical Trial Center, Taiwan
MOST Clinical Trial Consortium for Stroke
China Medical University Hospital
Tseng-Lien Lin Foundation, Taichung, Taiwan
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference34 articles.
1. Chronic obstructive pulmonary disease;Lancet,2022
2. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis;Lancet Respir. Med.,2022
3. GBD (2022, September 09). Institute for Health Metrics and Evaluation, Global Health Data Exchange, Global Burden of Disease Study 2019 (GBD 2019) Data Resources, GBD Results Tool, Terms And Conditions (2019). Available online: https://vizhub.healthdata.org/gbd-results/.
4. Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature;Respiration,2015
5. Do sulphonylureas still have a place in clinical practice?;Lancet Diabetes Endocrinol.,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献